Skip to content

Koebner's Phenomenon in Psoriasis and Lichen Planus

A Prospective Study to Investigate the Pathophysiology of the Koebner's Phenomenon in Psoriasis and Lichen Planus

Status
Withdrawn
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06021405
Acronym
RENBOEK
Enrollment
0
Registered
2023-09-01
Start date
2025-09-01
Completion date
2025-09-20
Last updated
2026-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kobner Phenomenon, Psoriasis, Lichen Planus

Brief summary

Psoriasis and lichen planus often occur at mechanically irritated skin sites (e.g. tight clothing). The investigators would like to investigate this phenomenon in more detail in this study. For this purpose, the skin is specifically irritated at a small and cosmetically favorable site by tearing off scotch tape or rubbing with a wooden spatula. In order to be able to examine the inflammatory processes caused by the irritation more closely, a small skin sample and a skin swab are taken from the irritated area. This skin sample and the swab are repeated after three and fourteen days.

Interventions

a small area of skin will be tape-stripped with adhesive tape for up to 40 times and/or rubbed with a wooden spatula until the skin shows a slight erythema

Sponsors

Marie-Charlotte Brüggen
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Dermatologist diagnosed psoriasis (group psoriasis), lichen planus (group lichen planus) or no skin disease (group healthy controls) * Subject is capable of giving informed consent * Signed informed consent

Exclusion criteria

* Use of systemic immunosuppressive/immunmodulating agents in the last three months * Use of topical anti-inflammatory treatment in the last 7 days in the area of sampling. * Phototherapy in the last 4 weeks * Active or recurrent serious bacterial, fungal or viral infection at the time of enrollment by patient history, including patients with Human Immunodeficiency Virus (HIV) infection, Hepatitis B and Hepatitis C infection, active or untreated latent tuberculosis. * Female patients of childbearing potential who are pregnant or breast feeding or planning a pregnancy during the duration of the trial and/or not practicing acceptable birth control for the duration of the trial * Known or suspected non-compliance, drug or alcohol abuse, * Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant, * Previous enrolment into the current study, * Enrolment of the investigator, his/her family members, employees and other dependent persons.

Design outcomes

Primary

MeasureTime frameDescription
Differences in the transcriptomic profile comparing psoriasis patients with and without induced koebner phenomenonDay 0, Day 3 (optional), Day 14 (optional)Transcriptomic profile at all timepoints (reads per 55µm diameter dot)

Secondary

MeasureTime frameDescription
Differences in the proteomic profile comparing psoriasis patients with and without induced koebner phenomenonDay 0, Day 3 (optional), Day 14 (optional)Olink multiplex proteomics analysis at all timepoints
Characterization of involved immune cells in the skin comparing psoriasis patients with and without induced koebner phenomenonDay 0, Day 3 (optional), Day 14 (optional)Imaging mass cytometry (skin biopsies) at all timepoints
Characterization of skin mikrobiomeDay 0, Day 3, Day 14Skin swabs at all timepoints, analyzed by isolation and sequencing of the microbial DNA

Contacts

PRINCIPAL_INVESTIGATORMarie-Charlotte Brüggen, MD PhD

University of Zurich

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 18, 2026